These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16020405)

  • 21. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
    Barnett AH
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S42-9. PubMed ID: 15868119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
    Tan F; Mukherjee JJ; Lee KO; Lim P; Liew CF
    Singapore Med J; 2010 Feb; 51(2):151-6. PubMed ID: 20358155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
    Ledingham JM; Laverty R
    Clin Exp Pharmacol Physiol; 2005; 32(1-2):76-85. PubMed ID: 15730439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis.
    Bozkurt D; Cetin P; Sipahi S; Hur E; Nar H; Ertilav M; Sezak M; Duman S
    Perit Dial Int; 2008 Nov; 28 Suppl 5():S38-42. PubMed ID: 19008539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
    Ravid M; Lang R; Rachmani R; Lishner M
    Arch Intern Med; 1996 Feb; 156(3):286-9. PubMed ID: 8572838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
    Ravid M; Savin H; Jutrin I; Bental T; Katz B; Lishner M
    Ann Intern Med; 1993 Apr; 118(8):577-81. PubMed ID: 8452322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of proteinuria with angiotensin receptor blockers.
    Galle J
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
    de Gasparo M; Hess P; Nuesslein-Hildesheim B; Bruneval P; Clozel JP
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):151-8. PubMed ID: 11967807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
    Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
    J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria.
    Smith DG; Nguyen AB; Peak CN; Frech FH
    J Manag Care Pharm; 2004; 10(1):26-32. PubMed ID: 14720103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of valsartan on lipid profile in normotensive type 2 diabetic patients.
    Velija-Asimi Z; Heljić B
    Med Arh; 2005; 59(5):311-2. PubMed ID: 16134756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor].
    Durruty P; Tapia JC; Ugarte C; Pérez E; Krause P; Soto N; García de los Ríos M
    Rev Med Chil; 1996 Sep; 124(9):1036-44. PubMed ID: 9197016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
    Kasama S; Toyama T; Hatori T; Sumino H; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
    Heart; 2006 May; 92(5):625-30. PubMed ID: 16159967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
    Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
    Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nomega-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats.
    de Gasparo M; Hess P; Clozel M; Persohn E; Roman D; Germann PG; Clozel JP; Webb RL
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):789-800. PubMed ID: 12409988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.